Evidence map›Paper›PMID 41857011›Full record

ArticleCell death discovery2026

FUT8 reprograms glycolytic metabolism to promote PKM2 lactylation and drive clear cell renal cell carcinoma progression.

Zikai Guo, Hongxiao Jiang, Xu Wang, Ke Xuan, Huidong Zhong, Chengxi Liu, Mengkai Zhang, Zhichao Li, Weiren Huang, Yangyang Sun

Abstract read
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zikai Guo *Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Hongxiao Jiang *The First Affiliated Hospital, Shenzhen University; Shenzhen Second People's Hospital; Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, Shenzhen, China.
Xu Wang *The Third Affiliated Hospital of Anhui Medical University (The First People's Hospital of Hefei), Hefei, China.
Ke XuanThe First Affiliated Hospital, Shenzhen University; Shenzhen Second People's Hospital; Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, Shenzhen, China.
Huidong ZhongDepartment of Oncology, Ji'an Central Hospital, Ji'an, China.
Chengxi LiuDepartment of Applied Biology and Chemical Technology, Food Safety and Technology Research Centre, and Research Centre for Chinese Medicine Innovation, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong SAR, China.
Mengkai ZhangThe First Affiliated Hospital, Shenzhen University; Shenzhen Second People's Hospital; Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, Shenzhen, China.
Zhichao LiThe First Affiliated Hospital, Shenzhen University; Shenzhen Second People's Hospital; Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, Shenzhen, China. liz_hichao@126.com.
Weiren HuangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. hwrpony@szu.edu.cn.ORCID http://orcid.org/0009-0003-8242-0518
Yangyang SunState Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China. sunyangyang06@163.com.ORCID http://orcid.org/0000-0002-4357-611X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82303247National Natural Science Foundation of China (National Science Foundation of China) 82473168
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is characterized by the loss of the von Hippel-Lindau (VHL) gene, leading to constitutive activation of hypoxia-inducible transcription factors (HIFs) and metabolic reprogramming toward aerobic glycolysis. Although core fucosylation catalysed by fucosyltransferase 8 (FUT8) is known to regulate receptor signaling and tumor malignancy, its role in metabolic regulation of ccRCC remains poorly defined. Here, we demonstrate that FUT8 knockdown significantly suppresses ccRCC proliferation and migration both in vitro and in vivo. Mechanistically, FUT8 enhances HIF-1α-driven glycolysis, increasing lactate production and promoting pan-lysine lactylation (pan-Kla). Specifically, FUT8 promotes pyruvate kinase M2 (PKM2) K115 lactylation, which boosts its enzymatic activity while reducing nuclear localization, thereby driving epithelial-mesenchymal transition and malignant progression. Collectively, our findings reveal the FUT8-HIF-1α-lactate-PKM2 axis as a key mechanism that links core fucosylation to metabolic reprogramming and malignant progression in ccRCC and highlights FUT8 as a promising therapeutic target.

Identifiers

PMID41857011
PMCPMC13039778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.